ArticleDrug discovery today2022
The current status of COVID-19 vaccines. A scoping review.
Article in Drug discovery today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Separation of 100 nm-sized nanoparticles using a poly-Lys-modified monolith column.RSC advances · 2025Article
- Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used.Vaccines · 2025Article
- Review
- Article
- Saponins: Research Progress and Their Potential Role in the Post-COVID-19 Pandemic Era.Pharmaceutics · 2023Review
- Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis.Frontiers in immunology · 2022Article
- The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.Frontiers in immunology · 2022Article
- No one listens to us, we know this, so we participated: Qualitative evidence from menstruation research during the COVID-19 pandemic.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.